Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Disease or Syndrome > Ocular Hypertension

Ocular Hypertension

Ocular hypertension is a condition characterized by an elevated intraocular pressure (IOP) without the presence of optic nerve damage or visual field loss.
It is a major risk factor for the development of primary open-angle glaucoma.
Patients with ocular hypertension may be asymptomatic, with the elevated IOP detected during routine eye examinations.
Effective management of ocular hypertension can help prevent the progression to glaucoma and preserve vision.
Reserchers can leverage PubCompare.ai's AI-driven reproducibility platform to optimzie their studies on ocular hypertension, locating protocols from liteerature, preprints, and patents, and using AI-driven comparisons to identify the best protocols and products.
This can improve the reproducibilitry and effieciency of ocular hypertension research.

Most cited protocols related to «Ocular Hypertension»

1
Comprehensive Ophthalmological Assessment Protocol for Glaucoma
Each participant underwent a complete ophthalmological examination at baseline, which included relevant medical history, blood pressure measurement, best-corrected visual acuity, slitlamp biomicroscopy, gonioscopy, Goldmann applanation tonometry, central corneal thickness measurement, dilated funduscopy, stereoscopic ophthalmoscopy of the optic disc with a 78-diopter lens, and simultaneous stereoscopic disc photography. In addition to photography, the structure of the optic disc and nerve fiber layer was measured with a variety of imaging devices, including the Heidelberg Retina Tomograph (Heidelberg Engineering, Heidelberg, Germany), GDx (Carl Zeiss Meditec, Dublin, California), and optical coherence tomography (Stratus OCT; Carl Zeiss Meditec). Tests of visual function included SAP, short-wavelength automated perimetry, and frequency doubling technology perimetry. See Table 2 for details of the examinations and tests completed at each visit. We tracked all systemic and ocular procedures and medications and any concurrent conditions that might affect vision.
This examination protocol is repeated annually for patients with glaucoma, ocular hypertension, and suspected glaucoma, who receive treatment and glaucoma medications at no cost at the discretion of their glaucoma specialist. Transportation is provided when needed.
All color simultaneous stereophotographs were taken using a Nidek Stereo Camera Model 3-DX (Nidek Inc, Palo Alto, California) after maximal pupil dilation. All photograph evaluations were performed using a simultaneous stereoscopic viewer (Asahi Pentax Stereo Viewer II; Pentax, Tokyo, Japan) with a standard fluorescent light bulb. Certified photograph graders evaluated all photographs. To be certified, individuals were trained and then tested on separate standardized sets of stereophotographs depicting (1) glaucomatous and healthy eyes and (2) progressing and nonprogressing eyes. Recent evidence from the Ocular Hypertension Treatment Study (OHTS) and the European Glaucoma Prevention Study indicated that reproducibility of stereophotograph assessment is good when graders have been trained using this type of formal protocol.16 (link),17 (link)
Each photograph was graded by 2 independent graders according to a standard protocol using the standard photographs as reference. Each grader was masked to the participant’s identity, diagnostic status, study, race, and other results. In cases of disagreement, a third senior grader adjudicated. All photographs were graded for quality and evidence of glaucoma damage. To assess between-grader reproducibility, 80 randomly chosen stereophotographs graded by IDEA (Imaging Data Evaluation and Analysis) Center personnel were evaluated for consensus between 2 graders; 73 of 80 (91%) were assigned the same diagnostic classification of glaucoma or healthy both times. Among the same 80 photographs, IDEA Center graders agreed on a vertical cup-disc ratio within 0.2 mm 70 of 80 times (87%). Adjudication of baseline photos was required in 31% of African descent and 28% of European descent eyes.
Sample P.A., Girkin C.A., Zangwill L.M., Jain S., Racette L., Becerra L.M., Weinreb R.N., Medeiros F.A., Wilson M.R., De León-Ortega J., Tello C., Bowd C, & Liebmann J.M. (2009). The African Descent and Glaucoma Evaluation Study (ADAGES): Design and Baseline Data. Archives of ophthalmology, 127(9), 1136-1145.
Publication 2009
Administration, Ophthalmic Corneal Pachymetry Determination, Blood Pressure Diagnosis Europeans Examination Tables Eye Glaucoma Glaucoma, Suspect Gonioscopy High Blood Pressures Lens, Crystalline Light Medical Devices Medulla Oblongata Mydriasis Negroid Races Nerve Fibers Ocular Hypertension Ophthalmoscopy Optic Disk Patients Perimetry Pharmaceutical Preparations Retina Slit Lamp Examination Tomography Tomography, Optical Coherence Tonometry, Ocular Vision Vision Tests Visual Acuity
2
Comprehensive Ocular Assessment of Glaucoma
All study subjects were recruited consecutively from the glaucoma service at the Massachusetts Eye and Ear Infirmary (MEEI) between April 2009 to July 2009. Each patient had a complete ophthalmologic examination, including history, visual acuity (VA) testing, refractive error exam, Goldmann applanation tonometry, slit-lamp biomicroscopy, gonioscopy, central corneal thickness by ultrasonic pachymetry, dilated ophthalmoscopy of the posterior segment, visual field (VF) testing [Swedish Interactive Threshold Algorithm (SITA) 24-2 test of the Humphrey visual field analyzer 750i, Carl Zeiss Meditec, Dublin, CA], and peri-papillary RNFL thickness measurements using the Spectralis OCT (Spectralis software version 4.0). Inclusion criteria included patients with a spherical equivalent between −5.0 diopters and +5.0 diopters and with best corrected VA of 20/40 or better. The study included only patients with reliable VF testing with acceptable fixation losses as defined by the Ocular Hypertension Treatment Study (OHTS) of less than 33% fixation losses.28 (link) Patients also had to have had less than 20% false positives and 20% false negatives. Exclusion criteria included patients with 1) any anterior segment dysgenesis, 2) corneal scarring or opacities, 3) proliferative or non-proliferative diabetic retinopathy, 4) field loss attributable to a non-glaucoma condition, 5) a dilated pupil diameter of less than 2 mm.
Participants included normal subjects and glaucoma patients. Normal subjects were those without significant ocular disease (except for mild cataract) and with normal VF test results that were defined as a pattern standard deviation (PSD) > 5% and glaucoma hemifield test (GHT) within normal limits.28 (link) Glaucoma patients included those with any form of chronic glaucoma except for traumatic glaucoma and were defined as having characteristic glaucomatous disc abnormality with corresponding VF loss. The VF was considered abnormal if three or more contiguous test locations in the pattern deviation plot were depressed significantly at the P < 5% level with at least 1 at the P < 1% level on the same side of the horizontal meridian, or was classified as outside normal limits by the GHT.29 (link) If both eyes of one subject fit inclusion and exclusion criteria, one eye was selected randomly by using a random number generator statistical table.
Wu H., de Boer J.F, & Chen T.C. (2011). Reproducibility of Retinal Nerve Fiber Layer Thickness Measurements Using Spectral Domain Optical Coherence Tomography. Journal of glaucoma, 20(8), 470-476.
Publication 2011
Administration, Ophthalmic Anterior segment mesenchymal dysgenesis Cataract Corneal Pachymetry Diabetic Retinopathy Glaucoma Gonioscopy High Blood Pressures Meridians Mydriasis Ocular Hypertension Ophthalmoscopy Patients POU5F1 protein, human Refractive Errors Slit Lamp Examination Tonometry, Ocular Ultrasonics Visual Acuity Visual Field Tests
3
Merging Sampling Distributions with Missing Data
The study examples were drawn from two systematic reviews [1 (link),17 (link)]. [17 (link)] reported a meta-analysis on drugs for patients with Type-2 diabetes and [1 (link)] reported a meta-analysis on lowering intraocular pressure for patients with open angle glaucoma or ocular hypertension.
In order to compare the results obtained from our methods with that from [17 (link)], we first attempted to collect all the original information on sampling distributions from each of the clinical trials papers used in [17 (link)]. After going through these papers, we found that we could not get the sampling distributions with full information from every single paper, as some of these papers did not provide the SEM values. We then applied our two methods to merge these (including partial) distributions and compared the merged result with that obtained in [17 (link)]. In contrast to [17 (link)], in [1 (link)] every sampling distribution used has full statistical information. To test the adequacy of our methods for dealing with missing information, we randomly selected a trial from [1 (link)] and deleted its SEM value. We then applied our two methods to recover this missing SEM value before merging this trial with the rest. Finally, we compared our results with that from [1 (link)].
Ma J., Liu W., Hunter A, & Zhang W. (2008). Performing meta-analysis with incomplete statistical information in clinical trials. BMC Medical Research Methodology, 8, 56.
Full text: Click here
Publication 2008
Diabetes Mellitus, Non-Insulin-Dependent Glaucoma, Open-Angle Ocular Hypertension Patients Pharmaceutical Preparations Pressures, Intraocular
4
Characterizing Glaucoma Subtypes Criteria

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2014
BAD protein, human Cataract Extraction Chambers, Anterior Congenital Abnormality Cornea Diabetic Retinopathy Eligibility Determination Glaucoma Glaucoma, Suspect Hemorrhage Lens Implantation, Intraocular Nerve Fibers Ocular Hypertension Operative Surgical Procedures Optic Disk Pathological Dilatation Perimetry Refractive Errors Retina Slit Lamp Examination Steroids Tonometry, Ocular Vision Visual Acuity
5
Corneal Dystrophy and Normal Cornea Study

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2012
Cataract Extraction Contact Lenses Cornea Corneal Diseases Corneal dystrophy, Fuchs' endothelial, 1 Diabetes Mellitus Ethics Committees, Research Eye Fuchs Endothelial Dystrophy Glaucoma Lens Implantation, Intraocular Lubricant Eye Drops Ocular Hypertension Operative Surgical Procedures Patients Phacoemulsification Pharmaceutical Preparations Pregnancy Slit Lamp Examination Surgeries, Refractive

Most recents protocols related to «Ocular Hypertension»

1
Dexamethasone-Induced IOP Elevation in Mice
Not available on PMC !

Example 1

Weekly periocular CF injections of DEX-Ac in both eyes in ANGPTL7 WT mice significantly elevated IOP in (see, FIG. 1). IOP measurements of DEX-Ac-treated (n=18) versus vehicle-treated (n=6) mice show IOP elevation from week 1 to 6; **p<0.01, ***p<0.001, ****p<0.0001. In contrast, weekly periocular CF injections of DEX-Ac in both eyes in ANGPTL7 KO mice did not elevate IOP (see, FIG. 1). IOP measurements of DEX-Ac-treated (n=20) versus vehicle-treated (n=12) ANGPTL7 KO mice showed no effect in IOP elevation from week 1 to week 6.

US11865134B2. Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitors (2024-01-09). Regeneron Pharmaceuticals, Inc. [US]. Inventors: Gaurang Patel [US], Ying Hu [US], Kavita Praveen [US], Giovanni Coppola [US], Goncalo Abecasis [US], Aris Baras [US], Carmelo Romano [US].
Full text: Click here
Patent 2024
Cardiac Arrest Eye Injections, Periocular Mus Ocular Hypertension
2
Healthy Adult Intraocular Pressure Protocol
All potential studies required measurement of IOP to be made with the Tono-Pen XL (TP) or Tono-Pen AVIA (TP) applanation tonometers and the Goldmann applanation tonometer (GAT), in the same subject, in a single session, with the subject sitting in an upright position, in accordance with standardized measurement instructions provided by each instruments’ manufacturer. All IOP measurements were required to be reported in mm Hg. Summary statistics which contained the means and standard deviations of TP and GAT IOP measurements were required, for each primary study.
All primary studies were required to report the number of individuals participating, the number of eyes included in the statistical summaries, whether only 1 eye or 2 eyes were reported for each subject, the mean age of subjects (all subjects must have been 17 years of age or older), the country in which the study was completed, and the setting in which the IOP measurements were made (hospital, out-patient clinic, clinician’s office, research laboratory).
All primary studies were required to provide a clear statement, that all subjects reported in the “healthy” or “control” groups were free from eye pathologies, for example, glaucoma, suspected glaucoma, ocular hypertension, corneal edema, inflammation, which would potentially effect IOP measurements. Eye health was assessed by patient history in combination with ophthalmological examination. Primary studies were not required to investigate IOP in healthy adult, as the study’s primary research objective; only that IOP measurements and associated required information could be extracted from the primary study.
In the event mean CCT and associated standard deviations from the means were reported in the primary study, in addition to TP and GAT IOP, this information was recorded and included in the database for descriptive purposes and subsequent secondary analyses. CCT measurements were not required for primary study inclusion in the meta-analysis of IOP.
All primary studies were required to provide a clear statement, the study had been preapproved by the facility’s Institutional Review Board or local Ethics Committee and conducted in accordance with the tenets of the World Medical Association Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects.
, & Keller W.J. (2023). International comparisons of intraocular pressures, as measured by Tono-Pen and Goldmann applanation tonometry, in healthy adults: A meta-analysis. Medicine, 102(10), e33078.
Publication 2023
Adult Edema, Corneal Ethics Committees, Research Glaucoma Glaucoma, Suspect Inflammation Ocular Hypertension Outpatients Patients Regional Ethics Committees
3
Glaucoma Screening and Enrollment Protocol
Study subjects were screened in advance and then approached during their routine ophthalmology visits for written consent. A total of 22 subjects were enrolled in the study. Of those enrolled, two subjects failed to return to receive the experimental intervention and were subsequently lost to follow-up. 20 subjects and 37 eyes were included in the study. All subjects were 18 years or older and diagnosed with glaucoma or determined to be a glaucoma suspect. A diagnosis of glaucoma was based on the identification of clinical glaucomatous retinal nerve fiber layer (RNFL) defects and optic nerve head (ONH) abnormalities, including global rim thinning, rim notching, disc hemorrhage, or two consecutive reliable visual field tests with glaucoma hemifield test (GHT) showing a mean deviation outside normal limits. A diagnosis of glaucoma suspect was based on having glaucomatous optic neuropathy, as described for the diagnosis of glaucoma, and/or having ocular hypertension (IOP > 21 mm Hg) with a most recent visual field test with GHT showing a mean deviation within normal limits. Criteria for exclusion included the presence of corneal opacities, such as scars and edema, pregnancy or planning to be pregnant, and an inability to fixate gaze.
The trial registration information is as follows:
The CONSORT participant flow diagram is shown in Fig 1.
Madu C.T., Phelps T., Schuman J.S., Zambrano R., Lee T.F., Panarelli J., Al-Aswad L, & Wollstein G. (2023). Automated 360-degree goniophotography with the NIDEK Gonioscope GS-1 for glaucoma. PLOS ONE, 18(3), e0270941.
Full text: Click here
Publication 2023
Cicatrix Congenital Abnormality Diagnosis Edema Glaucoma Glaucoma, Suspect Hemorrhage Nerve Fibers Neural-Optical Lesion Ocular Hypertension Optic Disk Pregnancy Retina Visual Field Tests
4
Laser-Induced Ocular Hypertension Model

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Adrenal Cortex Hormones Anesthesia Antibiotics Aqueous Humor Betamethasone Chambers, Anterior Eye Eye Drops Infection Inflammation Injections, Intraperitoneal Ketamine Light Coagulation Mus Ocular Hypertension Ointments Pharmaceutical Preparations Phenylephrine Hydrochloride Pupil Tropicamide Xylazine
5
Glaucoma Care Outcomes During COVID-19 Pandemic
We conducted a cross-sectional study between June 2020 and August 2020 involving patients attending the glaucoma clinic of Hospital Universiti Sains Malaysia (HUSM). HUSM is one of the tertiary eye care centres in the state of Kelantan, Malaysia. Kelantan is situated in the northeast of Malaysia, with an estimated population of 1.95 million [19 ].
During the three-month period from June through August 2020, we recruited all patients with glaucoma who attended our glaucoma clinic. Our inclusion criteria were confirmed cases of glaucoma with at least three previous visits within a year prior to March 18, 2020, and a pre-MCO IOP and best-corrected visual acuity (BCVA) recorded. We excluded those who were diagnosed with ocular hypertension, primary angle closure (PAC), or primary angle closure suspects (PACS). We also excluded those with pre-existing optic neuropathies.
We included 221 patients in the preliminary recruitment phase, and we traced their medical records. We excluded 27 patients from the final recruitment due to an inadequate number of pre-MCO follow-ups (19 patients) or because the IOP and BCVA were taken more than four months prior to MCO (eight patients). We obtained the pre-MCO IOP and BCVA from the medical record.
A thorough ocular examination was conducted, including slit-lamp biomicroscopy examination, fundus examination, and IOP measurement. Trained staff nurses did a visual acuity assessment using the Snellen chart. BCVA was included in our analysis. We used Goldmann applanation tonometry (Haag-Streit, Switzerland) to measure the IOP. A fundus examination was conducted using a 90D lens (VOLK, USA). Two experienced glaucoma specialists performed the vertical cup-to-disc ratio (VCDR) assessment. We recorded four clinical outcomes, which include missed medication, change of treatment, hospital admissions, or no change in treatment.
Missed medication was recorded when the patient was out of medication for more than two weeks prior to the recruitment period. A change of treatment was defined as any addition, switching, or changing of topical pressure-lowering drugs for uncontrolled IOP or failure to reach target pressure. Admission for uncontrolled IOP refers to any admission to the hospital due to uncontrolled IOP during the recruitment period. No change in treatment was when the target pressure was achieved without missing medication.
Primary open-angle glaucoma is a chronic progressive optic neuropathy with characteristic morphological changes at the optic nerve head and retinal nerve fibre layer, in the absence of other ocular disease or congenital anomalies. Angle-closure glaucoma is defined by the presence of iridotrabecular contact. A secondary glaucoma is a heterogeneous group of conditions, in which elevated IOP is the leading pathological factor causing glaucomatous optic neuropathy, either being open or closed angle [20 (link)]. We defined pre-MCO IOP and BCVA as the last IOP and BCVA taken no longer than four months prior to the MCO.
We performed our statistical analysis with the Statistical Analysis Software Package (SPSS), version 26 (SPSS Inc., Chicago, IL). We conducted double entries of the data to avoid incorrect entries or missing data. We analysed categorical data using the Pearson chi-squared test. We analysed numerical data such as IOP and VCDR using a paired t-test. A p-value of less than 0.05 was considered statistically significant.
Sidhu J.K., Yaakub A, & Ahmad Tajudin L.S. (2023). Lockdown: The Impact on Management of Glaucoma in a Suburban Tertiary Centre in Malaysia. Cureus, 15(1), e34412.
Full text: Click here
Publication 2023
Angle Closure Glaucoma Anophthalmos Congenital Abnormality Eye Genetic Heterogeneity Glaucoma Glaucoma, Primary Open Angle Hepatitis A Antigens Lens, Crystalline Nerve Fibers Neural-Optical Lesion Nurses Ocular Hypertension Optic Disk Patients Pharmaceutical Preparations Pressure Retina Slit Lamp Examination Specialists Tonometry, Ocular Visual Acuity

Top products related to «Ocular Hypertension»

1
Iol master by Zeiss
Sourced in Germany, United States, Ireland, Japan, United Kingdom, Lao People's Democratic Republic
The IOL Master is a non-contact optical biometry device used to measure various parameters of the eye, including axial length, anterior chamber depth, and corneal curvature. It provides precise measurements that are essential for calculating the appropriate intraocular lens power for cataract surgery.
2
Cirrus hd oct by Zeiss
Sourced in United States, Germany, Ireland, Japan
The Cirrus HD-OCT is a diagnostic imaging device developed by Zeiss. It utilizes optical coherence tomography (OCT) technology to capture high-resolution, cross-sectional images of the eye's internal structures, including the retina, optic nerve, and anterior segment. The device provides detailed visualization of these structures, enabling healthcare professionals to assess and monitor various ocular conditions.
3
Polybead microspheres by Polysciences
Sourced in United States, Germany
Polybead Microspheres are uniform, nonporous polymer microspheres that are available in a range of sizes and surface chemistries. These microspheres are designed for use as standards, markers, and tracers in various applications.
4
Xylazine by Bayer
Sourced in Germany, France, Japan, United States, Brazil, Spain, Canada, Switzerland, Cameroon, Australia, United Kingdom
Xylazine is a pharmaceutical product used as a sedative and analgesic in veterinary medicine. It is a central alpha-2 adrenergic agonist that produces a calming effect and pain relief in animals. Xylazine is used to facilitate handling, examination, and minor surgical procedures in various animal species.
5
Dba 2j mice by Jackson ImmunoResearch
Sourced in United States, Montenegro
The DBA/2J mouse is a widely used inbred laboratory mouse strain. It serves as a research model for various fields, including immunology, neuroscience, and genetic studies.
6
Tropicamide ophthalmic solution by Bausch & Lomb
Sourced in United States
Tropicamide ophthalmic solution is a pharmaceutical product manufactured by Bausch & Lomb. It is a clear, sterile solution for topical application to the eye. The active ingredient in this product is tropicamide, which is a mydriatic and cycloplegic agent.
7
Sterile physiologic saline by Thermo Fisher Scientific
Sterile physiologic saline is a sterile solution of sodium chloride in water, formulated to match the concentration of salts found in the human body. It serves as a general-purpose diluent and rinsing solution for laboratory applications.
8
Moxifloxacin hcl by Alcon
Moxifloxacin HCl is a broad-spectrum fluoroquinolone antibiotic used in laboratory settings. It is a crystalline powder that exhibits antimicrobial activity against a variety of gram-positive and gram-negative bacteria.
9
Spectralis oct by Heidelberg Engineering
Sourced in Germany, United States, United Kingdom, Japan
The Spectralis OCT is a high-resolution optical coherence tomography (OCT) imaging system designed for clinical use. It provides detailed, cross-sectional images of the eye's internal structures, enabling healthcare professionals to diagnose and monitor a variety of ocular conditions.
10
Silikon by Alcon
Sourced in United States
Silikon is a laboratory equipment product designed for performing various scientific experiments and analyses. It is a versatile tool that can be utilized in a wide range of applications within the scientific community.

More about "Ocular Hypertension"

Ocular Hypertension: Elevated Intraocular Pressure and Glaucoma Risk Ocular hypertension is a condition characterized by an abnormally high intraocular pressure (IOP) without any visible damage to the optic nerve or visual field loss.
It is a major risk factor for the development of primary open-angle glaucoma, a leading cause of blindness worldwide.
Patients with ocular hypertension may be asymptomatic, with the elevated IOP typically detected during routine eye examinations.
Effective management of ocular hypertension is crucial, as it can help prevent the progression to glaucoma and preserve vision.
Researchers can leverage advanced tools like PubCompare.ai's AI-driven reproducibility platform to optimize their studies on ocular hypertension.
This platform allows researchers to locate relevant protocols from the literature, preprints, and patents, and use AI-driven comparisons to identify the best protocols and products.
This can significantly improve the reproducibility and efficiency of ocular hypertension research.
Key topics and technologies related to ocular hypertension research include: - IOL Master: A device used to measure axial length and other biometric parameters of the eye, which are important in the diagnosis and management of ocular hypertension. - Cirrus HD-OCT: A high-definition optical coherence tomography (OCT) imaging system used to assess the structure of the optic nerve and retina, which can provide insights into ocular hypertension. - Polybead Microspheres: Microscopic beads used in animal models to induce ocular hypertension and study the disease progression. - Xylazine: A sedative and analgesic drug used in animal models of ocular hypertension. - DBA/2J mice: A mouse strain that develops a form of glaucoma similar to human open-angle glaucoma, often used in ocular hypertension research. - Tropicamide ophthalmic solution: A mydriatic (pupil-dilating) drug used in diagnostic procedures for ocular hypertension. - Sterile physiologic saline: A solution used to maintain the proper fluid balance in the eye during various ophthalmic procedures. - Moxifloxacin HCl: An antibiotic used to prevent and treat eye infections that may occur during ocular hypertension research. - Spectralis OCT: A high-resolution OCT imaging system used to evaluate the structure of the optic nerve and retina in ocular hypertension. - Silikon: A silicone oil used in the treatment of various eye conditions, including those associated with ocular hypertension.
By incorporating these related terms, technologies, and subtopics, researchers can enhance the comprehensiveness and SEO-optimization of their content on ocular hypertension, ultimately improving the discoverability and impact of their work.